Moleculin Biotech raises ~$9.3M in public offering of common stock and warrants

Moleculin Biotech, Inc.

Gross proceeds of ~$9.3M from sale of 12.4M shares and warrants at $0.75 per unit.
Warrants exercisable at $0.75 for five years; pre-funded warrants at $0.001.
Proceeds to fund Annamycin clinical development and working capital.
Lock-up agreements for officers/directors for 60 days; 45-day ban on further equity issuances.
Placement agent fees: 6.5% to Roth Capital, 1% to Maxim Group.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.